The invention relates to a method and a computer program for estimating a bilirubin level of a neonate, composed of the steps of: Acquiring a series of bilirubin levels estimated at different time points from a sample obtained from a neonate, Acquiring a plurality of covariates from the neonate, each composed of an information about a neonatal property, Providing a pre-defined bilirubin model function, wherein the bilirubin model function is configured to describe a time course of a bilirubin level of a neonate, Determining a plurality of model parameters of the bilirubin model function, wherein each model parameter is estimated from at least one covariate of the plurality of covariates and an associated population model parameter, Determining from the series of acquired bilirubin levels and the bilirubin model function with the determined model parameters an expected bilirubin level of the neonate for a time particularly later than a lastly acquired bilirubin level of the series of bilirubin levels.

A diagnostic system detects and/or measures hemoglobin variants in blood of subject, such as HbA1c, to determine blood glucose concentration in the subject.

A dose determination program for an erythropoiesis-stimulating agent that is executable by a computer. The program causes the computer to perform: obtaining a predetermined target hemoglobin concentration; obtaining a first concentration and a first dose in a stable state in which a hemoglobin concentration is stable at the first concentration by repeatedly administering the first dose a plurality of times, and calculating a second dose of the erythropoiesis-stimulating agent based on the obtained target hemoglobin concentration, the obtained first concentration, and the obtained first dose, the second dose of the erythropoiesis-stimulating agent being to be administered by a fixed amount.

A dose determination program for an erythropoiesis-stimulating agent that is executable by a computer. The program causes the computer to perform: obtaining a predetermined target hemoglobin concentration; obtaining a first concentration and a first dose in a stable state in which a hemoglobin concentration is stable at the first concentration by repeatedly administering the first dose a plurality of times, and calculating a second dose of the erythropoiesis-stimulating agent based on the obtained target hemoglobin concentration, the obtained first concentration, and the obtained first dose, the second dose of the erythropoiesis-stimulating agent being to be administered by a fixed amount.

The present disclosure relates to systems and methods for measuring glycated A1c hemoglobin. A glycated hemoglobin level measuring system includes a sample testing apparatus having a microchannel that compresses a blood sample traveling through, a first pair of electrodes coupled to the microchannel, and a second pair of electrodes coupled to the microchannel. The glycated hemoglobin level measuring system further includes an analysis apparatus having sensors coupled to the first and second pairs of electrodes and configured to calculate a travel time taken by a red blood cell to pass through the first and second pairs of electrodes. The glycated hemoglobin level measuring system can use the travel time to measure a rigidity of the red blood cells and the corresponding glycated hemoglobin level.

An optical blood monitoring system and corresponding method avoid the need to obtain a precise intensity value of the light impinging upon the measured blood layer during the analysis. The system is operated to determine at least two optical measurements through blood layers of different thickness but otherwise substantially identical systems. Due to the equivalence of the systems, the two measurements can be compared so that the bulk extinction coefficient of the blood can be calculated based only on the known blood layer thicknesses and the two measurements. Reliable measurements of various blood parameters can thereby be determined without certain calibration steps.

Systems and methods for measuring hemoglobin, G6PD activity, and or bilirubin activity in a sample, including measuring the absorbance of a sample, removing background interfering signals, and quantifying the relevant analyte. Systems and methods for reconstituting a reagent in a droplet actuator. Systems and methods for separating plasma from a whole blood sample on a droplet actuator, including combining a sample droplet with an agglutination reagent droplet and using a novel combination of droplet operations to split the sample into a plasma and an agglutinated red blood cell fraction.

Systems and methods for measuring hemoglobin, G6PD activity, and or bilirubin activity in a sample, including measuring the absorbance of a sample, removing background interfering signals, and quantifying the relevant analyte. Systems and methods for reconstituting a reagent in a droplet actuator. Systems and methods for separating plasma from a whole blood sample on a droplet actuator, including combining a sample droplet with an agglutination reagent droplet and using a novel combination of droplet operations to split the sample into a plasma and an agglutinated red blood cell fraction.

Technology described herein includes a method that includes obtaining an image of a fluid of a microfluidic analysis system. The microfluidic analysis system includes or receives a container that contains the fluid for measurement of analyte or quality determination. A region of interest (ROI) is identified based on the image. The ROI is a set of pixel values for use in the measurement of the analyte or the quality determination of the fluid, fluidic path, or measuring system. Identifying the ROI includes: determining an alignment of the container of the fluid with the imaging device based on the image, and identifying the ROI based on information about the measurement of the fluid or based on information about non-analyte features of the fluid. An analysis of the image of the fluid is performed using the set of pixel values of the ROI.

A test apparatus and method for measuring a concentration of a target by correcting for an impact of hemoglobin are provided. The target measurement method includes measuring an absorbance of hemoglobin in a sample, measuring an absorbance of a target in the sample, determining variation of the absorbance of the target according to the measured absorbance of the hemoglobin, and correcting the absorbance of the target by subtracting the determined variation of the absorbance of the target from the measured absorbance of the target.